Preklinik Modellerde Pulmoner Fibrozisin Gelişmiş Değerlendirmesi için Mikro-BT Kullanılarak Tek Taraflı Akciğer Hacmi Analizi

Executive Industry Relevance

Quantitative unilateral lung volume analysis using micro-CT enables precise assessment of pulmonary fibrosis progression and therapeutic response in preclinical models. This approach addresses the need for reproducible, sensitive, and translationally relevant endpoints in early-stage respiratory drug discovery. Enhanced volumetric and regional quantification supports confident decision-making at key inflection points in fibrosis portfolio advancement.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables rigorous interrogation of fibrotic pathway hypotheses in vivo.
• Supports functional target validation by quantifying lesion-specific lung volume changes.
• Facilitates mechanistic de-risking through precise regional injury modeling.
• Improves predictive confidence for candidate selection in fibrosis programs.

Screening & Assay Development

• Provides standardized, quantitative readouts for evaluating anti-fibrotic interventions.
• Enables reproducible assessment of ventilated lung regions across cohorts.
• Supports assay scalability and platform reuse for longitudinal studies.
• Delivers reliable volumetric endpoints for compound screening workflows.

Translational & Preclinical Research

• Aligns preclinical endpoints with clinically relevant imaging modalities.
• Enables continuity from discovery through preclinical validation of therapeutic efficacy.
• Supports risk-adjusted advancement decisions based on quantitative disease progression metrics.
• Facilitates biomarker alignment through imaging-based fibrosis assessment.

Pipeline & Workflow Integration

This micro-CT-based volumetric analysis integrates into the discovery-to-preclinical continuum for pulmonary fibrosis, bridging early mechanistic studies and translational efficacy evaluation.

• Discovery Biology: Supports hypothesis testing and biological de-risking by quantifying regional fibrotic injury.
• Screening: Provides reproducible, quantitative outputs for intervention assessment and cohort comparison.
• Analytics: Delivers volumetric and aeration metrics to inform statistical analysis and decision thresholds.
• Translational Research: Aligns preclinical imaging endpoints with clinical diagnostic standards.
• Enterprise Reuse: Establishes a reusable imaging and analysis workflow for fibrosis and related lung disease models.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in fibrosis models.
• Operational Value: Standardizes volumetric analysis and enhances reproducibility across studies.
• Strategic Value: Enables informed go/no-go decisions and capital-efficient portfolio progression.
• Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory assets.

Implementation Considerations

• Requires expertise in micro-CT imaging and 3D image analysis software.
• Demands access to high-resolution micro-CT instrumentation and computational infrastructure.
• Necessitates cross-team standardization of imaging protocols and analysis parameters.
• Adaptation may be needed for different animal models or fibrosis etiologies.
• Potential limitations include imaging throughput and segmentation accuracy, especially in severe disease states.

Biopharma FAQs